Jn.1
Enhanced immune evasion ability propels it to become the predominant strain in China, unlikely to trigger pandemic similar to late 2022
Bibliographic Data
| ID | 22073093 |
|---|---|
| Authors | Peng Du (0000-0002-6576-3741, Macau University of Science and Technology), Meiyi Li (0000-0002-0178-7883, Guangzhou Medical University), Guohui Wei (0000-0001-6636-485X), Chengbin Guo (Macau University of Science and Technology), Ning Li (0000-0003-4098-1838, Guangzhou Medical University, corresponding author) |
| Year | 2024 |
| Volume | 12 |
| Pages | 1442291-1442291 |
| Publication date | 2024-09-26 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2024.1442291 |
| PMID | 39391153 |
| OpenAlex | W4402894664 |
| Language | EN |
| References cited | 27 |
Introduction: Due to the widespread presence of susceptible populations, the pandemic caused by BA.5 subbranches swiftly disseminated China, impacting the majority of individuals within a span of 1 to 2 months. Subsequently, XBB and its subbranches became the dominant variants in China. Methods: We tracked the immune landscape in the population after the SARS-CoV-2 pandemic in late 2022 in China. Results: Our findings suggested that low levels of neutralizing antibodies against BA.5 subbranches before the pandemic might have contributed to the national outbreak at the end of 2022. The widespread breakthrough infections subsequently increased immunity to BA.5, XBB.1.5/1.9.1, and JN.1, inhibiting a new wave of large-scale infections caused by XBB subbranches in China. Additionally, JN.1 demonstrated enhanced immune evasion capabilities; however, Chinese residents had comparable levels of neutralizing antibodies against JN.1 as those observed for XBB.1.5 among confirmed cases at the end of 2022. Discussion: We anticipate that JN.1 will replace XBB subbranches as the predominant epidemic variant in subsequent transmissions within China. However, it is unlikely to cause a large-scale spread comparable to that witnessed at the end of 2022, with transmission patterns potentially resembling those observed for XBB post-pandemic
Antibody · Biology · China · Disease · Environmental health · Geography · Immune system · Immunity · Outbreak · Pandemic · Population · Invertebrate Immune Response Mechanisms · Medicine · SARS-CoV-2 and COVID-19 Research · vaccines and immunoinformatics approaches · Immunology · Internal Medicine · Virology
| Highly cited | No |
|---|